A Putative Frizzled 7-Targeting Compound Acts as a Firefly Luciferase Inhibitor

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Frizzled family (FZD1-10) receptors regulate WNT signaling, crucial for cell proliferation.
• Aberrant FZD7 and WNT/β-catenin signaling are implicated in intestinal cancers, making FZD7 a therapeutic target.
• Targeting FZD7 offers a promising strategy for developing novel cancer treatments.

Purpose of the Study:

• To evaluate compound 28, identified via virtual screening, as a potential FZD7 inhibitor for cancer therapy.
• To validate the inhibitory effects of compound 28 on WNT/β-catenin signaling.
• To investigate the mechanism of action of compound 28 and its specificity.

Main Methods:

• Structure-based virtual screening to identify potential FZD7 inhibitors.
• TOPFlash reporter gene assay to assess WNT/β-catenin signaling inhibition.
• Pharmacological validation using Firefly luciferase (Fluc) inhibition assays.
• Fluc-independent assays including bioluminescence resonance energy transfer (BRET) biosensors and quantitative PCR (qPCR).

Main Results:

• Compound 28 was identified as a potent inhibitor of Firefly luciferase (Fluc) with an IC50 of 30 nM.
• Compound 28 did not inhibit WNT/β-catenin signaling as measured by Fluc-independent assays.
• Fluc-independent assays demonstrated that compound 28 failed to inhibit WNT-3A-induced FZD7 conformational changes and Axin2 gene transcription.

Conclusions:

• Compound 28 acts as a luciferase inhibitor, not a specific FZD7 or WNT pathway inhibitor.
• The study underscores the critical importance of implementing counter screens to validate findings from initial compound screening.
• False positives due to assay interference necessitate rigorous validation to ensure therapeutic candidate efficacy and specificity.